Evidence-based pharmacological interventions for insomnia: a systematic review on the effects of eszopiclone on insomnia comorbid with mental disturbances.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·April 1, 2026·PMID: 41840848

What's New

Eszopiclone as adjunctive treatment was associated with alleviation of insomnia symptoms and improvements in psychiatric measures across multiple mental health conditions.

Detailed Summary

A systematic review following PRISMA guidelines identified 12 studies examining eszopiclone use in insomnia comorbid with psychiatric disorders, including major depression, anxiety-related disorders, and schizophrenia. Overall data indicated that adjunctive eszopiclone was associated with reduced insomnia symptoms and showed positive correlations with depressive, anxiety, and cognitive outcomes.

Study Population

individuals with insomnia comorbid with psychiatric disorders, including major depression, anxiety-related disorders, and schizophrenia

This research is for informational purposes only — discuss with your doctor before making any changes to your care.

Discuss This with a Sleep Medicine Specialist

Rivvet may earn a referral fee if you book through this link.

Share:
Share on X

Want more research like this? Sign up free